Open Research Trials at Sibley Memorial Hospital
Please contact Jackie Lobien at (301) 896-3122 or by email email@example.com to learn about the clinical trials offered at Sibley.
Updated: February 24, 2014
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Can
Johns Hopkins Breast Cancer Program Longitudinal Repository
Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database
J1232 (DIG-HIF1 PK)
Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with ER Negative Early Stage Breast Cancer
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer
Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 GM-CSF Vaccine versus GM-CSF Alone in HLA-A2 OR the Modified HER2/neu Peptide AE37 GM-CSF Vaccine versus GM-CSF alone in HLA-A2- Node-Positive and High Risk Node-Negative Breast Cancer Patients to Prevent Recurrence
A Phase III trials of 6 versus 12 treatment of Adjuvant Treatment of Adjuvant Folfox plus Celecoxib or Placebo for patient with Resected Stage III Colon Cancer.
STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) Vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
A Randomized double-blinded Phase III study comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin,and Placebo in patients with advanced Transitional Cell Carcinoma
A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
A Phase I study of the mTOR inhibitor Temsirolimus in combination with the HDAC inhibitor Vorinostat in patients with metastatic prostate cancer
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate
Phase I/II study of safety and efficacy of Muscadine Plus (MPX) in men with prostate cancer: A randomized, double-blind, placebo-controlled study of the effects of two doses of MPX capsule on rising prostate-specific antigen in men following initial ther
A Randomized Gene Fusion Stratified Phase 2 Trial Of Abiraterone With Or Without ABT 888 For Patients With Metastatic Castration-Resistant Prostate Cancer (NCI# 9012)
Phase II Trial to Evaluate Benefit of Early Switch from first-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the opposite sequence, exploring molecular markers and mechanisms of taxane resistance in men with Metastatic Castration-Resistant Prost
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies: A Pilot/Feasibility Study
A Phase II Study of Bipolar Androgen-based Therapy for Men with Androgen Ablation Naïve Recurrent Prostate Cancer
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy
A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy TAK-700 With Androgen Deprivation Therapy Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer (ARN-509-003)
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
A Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy.
A Phase III Randomized study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy In High-Risk Patient With Early-Stage Cervical Carcinoma Following Radical Hysterectomy
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin In Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Phase III Randomized Trial of Gemcitabine plus Docetaxel Followed by Doxorubicin versus Observation for Uterus-Limited High-Grade Uterine Leiomyosarcoma
There are no open studies at this time.
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
There are no open studies at this time.
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α- 2b for Resected High-Risk Melanoma